Shin J Oh
Overview
Explore the profile of Shin J Oh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh S
Muscle Nerve
. 2024 Jul;
70(4):731-732.
PMID: 39072842
In 2016, MLOS (myasthenia gravis Lambert-Eaton overlap syndrome) was coined to represent an entity of overlap syndrome of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Fifty-five MLOS patients have been identified....
2.
Oh S
J Clin Neurol
. 2024 Jul;
20(4):353-361.
PMID: 38951970
In 1983, the first successful trial of 3,4-diaminopyridine (3,4-DAP) in Lambert-Eaton myasthenic syndrome (LEMS) was reported. Efficacy of amifampridine (3,4-DAP and 3,4-diaminopyridine phosphate [3,4-DAPP]) for symptomatic treatment in LEMS was...
3.
Oh S
J Clin Neuromuscul Dis
. 2024 Mar;
25(3):163-170.
PMID: 38441938
Objectives: In 2015, a new term "nodopathy" was introduced to represent a group of neuropathy because of autoantibodies at the node of Ranvier and paranodal area. This review was conducted...
4.
Oh S, King P
J Clin Neurol
. 2024 Feb;
20(3):276-284.
PMID: 38330421
Background And Purpose: To report an improvement with immunotherapy in 34 (85%)/40 patients who required an immunotherapy among 56 patients with sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods: Sensory CIDP...
5.
Oh S, King P, Schindler A
J Clin Neuromuscul Dis
. 2022 Nov;
24(2):80-84.
PMID: 36409338
Docking protein 7 (DOK7) congenital myasthenic syndrome (CMS) is characterized by limb-girdle weakness and lack of fluctuating fatigability simulating many familial myopathies. Albuterol is the first line of therapy in...
6.
Oh S
Curr Opin Neurol
. 2021 Dec;
34(5):648-657.
PMID: 34914667
Purpose Of Review: To give an overview of the recent data on three autoimmune neuromuscular junction disorders with the recent Food Drug Administration (FDA) approval of amifampridine [3,4-Diaminopyridine (3,4-DAP) and...
7.
8.
Grunseich C, Sarkar N, Lu J, Owen M, Schindler A, Calabresi P, et al.
J Neurol Neurosurg Psychiatry
. 2021 Jun;
92(11):1186-1196.
PMID: 34103343
Background: We used a multimodal approach including detailed phenotyping, whole exome sequencing (WES) and candidate gene filters to diagnose rare neurological diseases in individuals referred by tertiary neurology centres. Methods:...
9.
Oh S
Muscle Nerve
. 2020 Nov;
63(2):178-180.
PMID: 33184867
A newly introduced term, "axonal conduction block," brought a confusion in the electrodiagnostic diagnosis of Guillain-Barrè syndrome (GBS). I am proposing the term "nodal conduction block" for "axonal conduction block."...
10.
Oh S, Lu L, Alsharabati M, Morgan M, King P
J Neurol Neurosurg Psychiatry
. 2020 Sep;
91(11):1175-1180.
PMID: 32917820
Objectives: Chronic inflammatory axonal polyneuropathy (CIAP) is defined on the basis of the clinical, electrophysiological and nerve biopsy findings and therapeutic responses of 'immunotherapy responding chronic axonal polyneuropathy (IR-CAP)'. Methods:...